Neuralstem Reports Year End 2016 Fiscal Results and Business Update
Mar 23, 2017 11:35 am UTC| Business
Expects to Report NSI-189 Phase 2 major depressive disorder studyresults in Q3 ahead of schedule GERMANTOWN, Md., March 23, 2017 -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development...
DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug
Mar 23, 2017 11:34 am UTC| Business
PHOENIX, March 23, 2017 -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or the “Company") today announced that the Drug Enforcement Agency (“DEA”) has issued an interim final rule that would result in Syndros™...
Mar 23, 2017 11:30 am UTC| Business
Full-year 2016 revenues up 50% year-over-year to $27 million from $18 millionFourth quarter revenues up 32% year-over-year on strong organic growth to $7.2 millionFourth quarter gross profit margins expand over three-fold...
Mar 23, 2017 11:30 am UTC| Business
VIENNA, Va. AND SOUTH SAN FRANCISCO, Calif., March 23, 2017 -- Origent Data Sciences, Inc. (Origent) and Cytokinetics, Inc. (Nasdaq:CYTK) today announced the advancement of their research collaboration to prospectively...
Mar 23, 2017 11:30 am UTC| Business
SAN DIEGO, March 23, 2017 -- Mad Catz Interactive, Inc. (the “Company”) (NYSE MKT:MCZ), today announced that it received notification that, due to the “abnormally low trading price” of its common stock, the staff of...
FTI Consulting Honored With 16 M&A Advisor Turnaround Awards
Mar 23, 2017 11:30 am UTC| Business
WASHINGTON, March 23, 2017 -- FTI Consulting, Inc. (NYSE:FCN) today announced that the firm has been recognized in 16 categories by the 11th Annual MA Advisor Turnaround Awards. “We are honored to be recognized by The...
Mar 23, 2017 11:30 am UTC| Business
On Track to Resubmit NDA for lutetium Lu 177 dotatate (Lutathera®) to FDA in Mid-2017 Conference Call Today at 10:00 a.m. ET 2016 Key Events: Sales for full-year 2016 increased 23% compared to 2015Closed $150 million...